Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly (NYSE:LLY) recently announced its plans to invest $27 billion in four new U.S. manufacturing plants over the next five years, creating thousands of jobs. This move comes at a time when ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on ...

Given the large stake in the stock by institutions, Foghorn Therapeutics' stock price might be vulnerable to their trading decisions The top 5 shareholders own 50% of the company Using data from ...

Given the large stake in the stock by institutions, Foghorn Therapeutics' stock price might be vulnerable to their trading decisions The top 5 shareholders own 50% of the company Using data from ...

Magnet Bio and Eli Lilly entered into a collaboration that could reach $ ... Adaptive deep brain stimulation device for people with Parkinson’s disease. Entrada Therapeutics announced that the FDA ...

Verve plans to deliver the opt-in data package for the PCSK9 program and receive a decision from Eli Lilly and Company ... any obligation to do so. Verve Therapeutics NewsMORE Related Stocks ...

Verve plans to deliver the opt-in data package for the PCSK9 program and receive a decision from Eli Lilly and Company (Lilly) in the second half of 2025. VERVE-201 is a novel, in vivo ...